Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
about
Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled TrialsRibavirin: Past, present and futureAnalysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionAbbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C PatientsGene expression and hepatitis C virus infectionPerformance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA QuantificationCombinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon systemHepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical PracticeOptimizing the dose and duration of therapy for chronic hepatitis C.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingA mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic ResponseMeta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Peginterferon and ribavirin treatment for hepatitis C virus infectionInterferon in the treatment of chronic hepatitis C: a drug caught between past and future.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Cost-effectiveness of screening for hepatitis C in Canada.Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.Impact of ribavirin dose on retreatment of chronic hepatitis C patientsA reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm.The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA.Ribavirin in the treatment of chronic hepatitis C.Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.Optimizing the treatment of chronic viral hepatitis C.25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis CHepatitis C variability, patterns of resistance, and impact on therapyDAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
P2860
Q26745895-612FB3AE-47F8-462A-AED1-5E2226EAF019Q26775002-CBAD93EB-5354-4F7E-9D72-C52BCEB36D8DQ27480933-7DCCF80E-DB40-4688-B3AC-19AB10E4E39AQ27487942-5D5442F4-A9B3-4C2D-9640-42CD70F3E8E7Q27488345-9A315A11-1CF1-4E90-9E34-53980AD192A6Q27488563-E71B1873-8096-45B0-AE33-B701FEBE84ACQ27489596-4B111907-4397-4A2A-A87B-B564063BE007Q27490447-0E067798-AEBF-48D2-9914-E57B138FE120Q33855483-18DA0A86-E77D-401C-9A84-DC2BE13C6DCDQ33899320-4940EE27-575B-4D80-A948-41D6E5EC7612Q33906899-2C7135BB-A268-47C7-A694-D0A6C44A4AE3Q33956478-F89852D6-E892-4B43-98E0-4ECDB81AD47AQ34334776-B9807D89-3928-4450-8459-5BE25A1EEDCBQ34409020-28DF3FDC-F35F-4450-B685-DD4D86C54D32Q34521371-6EE46327-197C-4AD8-9309-14504ECF1D63Q34626479-A3F02A5A-6EC1-4D75-B077-36838A4C477EQ34996746-B3F62EA0-0B68-4D60-B72A-AE918085BC61Q35088460-61A8180D-B1B2-4DD8-8F15-DF1278EB21D0Q35893868-8F7D4AE5-77B0-4EBF-B77F-9866CF98C39AQ36049907-0C371897-D15C-4910-BDA0-AA6B5926CE56Q36306694-2C207436-9D3D-471B-9F93-A2C3F0A6C5FAQ36736241-ACEFF819-1B89-45BB-8E6E-31E14F4B1276Q36884431-5A47E026-4745-4611-B7B1-C7D15E74A88CQ37195248-6C000F88-8351-4009-B320-B78B2C3AFEECQ37627878-64ED685F-F6AA-4E18-9002-F97871B3E7FEQ37636095-8FF90F43-ADC1-45A2-A146-BA2E73FA47A5Q37741812-228185A6-A952-475C-AEC9-A0B08F3C8ACDQ37765571-FF96D4B3-1896-4DDF-996B-EC0E15C3D385Q37772959-841AB51C-FEB8-46B8-882B-27B24E307CF7Q37846232-35581A84-9C50-44C0-AB51-EC7069EDAAE4Q37939247-FD32B9DF-D88F-4090-BDF4-EA766B3C5E92Q37972768-39AB219F-D961-4161-BEE3-6A2C33640F37Q37972769-2FDE2070-9F40-46D4-945B-68B5163DD7E8Q37990840-28D3163F-5458-4788-A500-80F576E8B9EDQ38073656-DE8C5E61-FA1F-407E-8391-AF90C1969B5FQ38530211-8EAA57FC-F5BB-40D1-A18D-EE592FC9877FQ38848491-7E03A1A6-34D1-4F30-98F7-257D2C91256CQ38915259-6AE24B42-B356-4551-934D-EF337A7ED7EEQ39576325-3139C9C5-8461-48BD-91FA-2F296EEE2A6EQ39749560-CB81641B-4F4D-4424-B68B-A8B19E4FBB7C
P2860
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@en
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@nl
type
label
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@en
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@nl
prefLabel
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@en
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@nl
P2093
P50
P1433
P1476
Effect of ribavirin in genotyp ...... rferon alfa-2a plus ribavirin.
@en
P2093
Albert Tran
Christophe Hézode
Christophe Renou
Denis Ouzan
François Montestruc
Hervé Desmorat
Isabelle Lonjon-Domanec
Jean-Pierre Bronowicki
Jean-Pierre Zarski
Juliette Foucher
P304
P356
10.1053/J.GASTRO.2006.07.022
P407
P577
2006-07-24T00:00:00Z